NCT04182659

Brief Summary

This study aims to look at the long term efficacy of using repetitive transcranial magnetic stimulation (rTMS) in relieving Gulf War Illness related headaches and pain.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2019

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 27, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 2, 2019

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2023

Completed
Last Updated

August 9, 2023

Status Verified

August 1, 2023

Enrollment Period

4 years

First QC Date

November 27, 2019

Last Update Submit

August 7, 2023

Conditions

Keywords

rTMSTranscranial Magnetic StimulationGulf War Illness

Outcome Measures

Primary Outcomes (11)

  • Change from baseline to post treatment of GWI-related pain and headaches

    This outcome will be measured through daily self-reporting logs that tracks headache, muscle, and joint pain. A numerical rating scale of 0, being no pain, to 10, being worst possible pain, will be used to report pain and headaches.

    Baseline, 1-week, 1-month, 2-month, and 3-month

  • Change from baseline to post treatment of sensory and affective aspects of pain

    Short Form McGill Pain Questionnaire (SF-MPQ): This is a self-report questionnaire that allows individuals to describe the quality and intensity of pain they are experiencing. This will be used to assess the sensory and affective aspects of muscle and joint pain.

    Baseline, 1-week, 1-month, 2-month, and 3-month

  • Change from baseline to post treatment of headaches

    The Headache Impact Test (HIT-6) will be used to measure how headaches affect the individual's ability to function in different domains. This 6-question form assesses the severity of headache pain and is scored with a range of 36-78, with higher scores indicating a larger impact of headaches on functionality.

    Baseline, 1-week, 1-month, 2-month, and 3-month

  • Change from baseline to post treatment of quality of life

    The Short Form Health Survey-36 (SF-36) is a self-reported survey of patient health. It is a measure of health status and quality of life in regards to eight main areas: vitality, physical functioning, bodily pain, health perceptions, physical, emotional, and social role functioning and mental health.

    Baseline, 1-week, 1-month, 2-month, and 3-month

  • Change from baseline to post treatment of body pain

    A Brief Pain Inventory-Short Form (BPI-SF) questionnaire will also be used to assess the severity of pain and the impact of pain on daily functions. The BPI-SF consists of five questions. Four items measure pain on 11-point response scales from 0 to 10 ("No Pain" to "Pain as bad as you can imagine". Another item, containing 7 sub-questions, evaluates the level of pain interference with daily functioning on 11-point response scales from 0 to 10 ("Does not interfere" to "Completely interferes").

    Baseline, 1-week, 1-month, 2-month, and 3-month

  • Change from baseline to post treatment of muscle pain

    The New Clinical Fibromyalgia Diagnostic Criteria - Part 1 will be used to assess muscle pain. Patients will be asked to rate the average (over the past 24 hours) intensity of muscle pain for up to 12 locations of the body.

    Baseline, 1-week, 1-month, 2-month, and 3-month

  • Change from baseline to post treatment of fibromyalgia

    A Revised Fibromyalgia Impact Questionnaire will be used to evaluate the function, overall impact and symptoms of Fibromyalgia. There are a total of 21 questions, each with a range of 0-10, with 10 being either "very difficult" or "always."

    Baseline, 1-week, 1-month, 2-month, and 3-month

  • Change from baseline to post treatment of neurobehavioral symptoms

    Baseline, 1-week, 1-month, 2-month, and 3-month

    The Neurobehavioral Symptoms Inventory (NSI) is a self-report questionnaire on the severity of various behavioral symptoms and is measured using a 5-item scale. It asks the subjects to indicate the extent to which each symptom has disturbed them.

  • Change from baseline to post treatment of sleep quality

    The Pittsburgh Sleep Quality Index (PSQI) questionnaire has nineteen individual items which are used to generate seven composite scores on: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Questions are either free-response or have a range from 0-3, with 3 being "more frequent" or "very bad."

    Baseline, 1-week, 1-month, 2-month, and 3-month

  • Change from baseline to post treatment of sleep difficulties

    The Insomnia Severity Index measures the severity of an individual's sleep difficulties. All questions range from 0-4 and the sum of the answers would give the total score. The total score range from 0-28.

    Baseline, 1-week, 1-month, 2-month, and 3-month

  • Change from baseline to post treatment of fatigue

    The Flinders Fatigue Scale measures daytime fatigue associated with insomnia through a 7-item questionnaire. The questions range from 1-5, with 5 being "extremely" or "entirely."

    Baseline, 1-week, 1-month, 2-month, and 3-month

Secondary Outcomes (3)

  • Change from baseline to post treatment of PTSD symptoms

    Baseline, 1-week, 1-month, 2-month, and 3-month

  • Change in opioid-based pain medication usage

    Baseline, 1-week, 1-month, 2-month, and 3-month

  • Explore changes in supraspinal resting state functional connectivity

    Baseline and 1-week post treatment

Study Arms (2)

Active rTMS at the LMC

ACTIVE COMPARATOR

Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left motor cortex (LMC)

Device: Transcranial Magnetic Stimulation

Sham rTMS at the LMC

SHAM COMPARATOR

Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LMC.

Device: Sham Transcranial Magnetic Stimulation

Interventions

A non-invasive treatment that emits magnetic pulses to stimulate the brain.

Active rTMS at the LMC

Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.

Sham rTMS at the LMC

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female under 65 years of age who served in the military for at least 30 consecutive days between August 1, 1990, and July 31, 1991 in the Persian Gulf War region
  • Center for Disease Control (CDC) Criteria for Gulf War Illness (GWI)
  • Kansas Criteria for GWI
  • International Headache Society Criteria for Migraine Headache without aura Average Headache Exacerbation Intensity \>3 on 0-10 a Numerical Pain Rating scale (NPS)
  • Average Overall Daily Muscle Pain Intensity \>3 on 0-10 a NPS
  • Average Overall Daily Extremities Joint Pain Intensity \>3 on 0-10 a NPS
  • Headache Exacerbation/attack 3 times per week with the average intensity \>3 on a 0-10 NPS, lasting \> 4 hours in the past three months
  • Hamilton Rating Scale of Depression (HRSD) \<14 based on the sum of scores for the first 17 items

You may not qualify if:

  • Pregnancy
  • History of pacemaker implant
  • Any ferromagnetic (e.g. bullet fragment, shrapnel, device implant) in the brain or body that will prohibit the patients from having a brain MRI
  • History of dementia, major psychiatric diseases, or life-threatening diseases
  • Presence of any other chronic neuropathic pain states such as Complex Regional Pain Syndrome or Painful Peripheral Neuropathy
  • History of seizure
  • Pending litigation
  • Low back pain with mechanical origins such as lumbar radiculopathy or radiculitis or lumbar facet arthropathy
  • Lack of ability to understand the experimental protocol and to adequately communicate in English
  • History of Traumatic Brain injury
  • Chronic Tension or Cluster Headache
  • Ongoing Cognitive Rehabilitation or Treatment of PTSD

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

VA Palo Alto

Palo Alto, California, 94304, United States

RECRUITING

VA San Diego Healthcare System

San Diego, California, 92161, United States

RECRUITING

VA Atlanta

Decatur, Georgia, 30033, United States

RECRUITING

MeSH Terms

Conditions

Persian Gulf SyndromeHeadacheMyalgiaArthralgia

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

Occupational DiseasesWar-Related InjuriesWounds and InjuriesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsMuscular DiseasesMusculoskeletal DiseasesNeuromuscular DiseasesNervous System DiseasesMusculoskeletal PainJoint Diseases

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Study Officials

  • Albert Leung, M.D.

    San Diego Veterans Healthcare System

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Caleb Lopez, BS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Masking Details
This is a double-blinded study where only the statistician is aware of the randomization.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: There are two groups: one will receive active rTMS and the other group will receive sham rTMS.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 27, 2019

First Posted

December 2, 2019

Study Start

October 1, 2019

Primary Completion

September 30, 2023

Study Completion

September 30, 2023

Last Updated

August 9, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

Locations